Geneos Wealth Management Inc. Sells 37 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Posted by Defense World Staff on Apr 14th, 2023

Geneos Wealth Management Inc. lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) by 3.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,086 shares of the biopharmaceutical company’s stock after selling 37 shares during the period. Geneos Wealth Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $784,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the stock. PGGM Investments purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $30,775,000. TrueWealth Advisors LLC bought a new stake in Regeneron Pharmaceuticals in the 3rd quarter worth $207,000. Ameritas Advisory Services LLC purchased a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at about $205,000. Wipfli Financial Advisors LLC bought a new position in Regeneron Pharmaceuticals during the 3rd quarter valued at approximately $555,000. Finally, US Bancorp DE raised its holdings in shares of Regeneron Pharmaceuticals by 1.3% during the third quarter. US Bancorp DE now owns 5,783 shares of the biopharmaceutical company’s stock valued at $3,984,000 after acquiring an additional 74 shares in the last quarter. 84.25% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CFO Robert E. Landry sold 739 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, February 3rd. The stock was sold at an average price of $764.50, for a total value of $564,965.50. Following the sale, the chief financial officer now owns 32,105 shares of the company’s stock, valued at approximately $24,544,272.50. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, CFO Robert E. Landry sold 739 shares of the company’s stock in a transaction dated Friday, February 3rd. The shares were sold at an average price of $764.50, for a total transaction of $564,965.50. Following the sale, the chief financial officer now directly owns 32,105 shares in the company, valued at approximately $24,544,272.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Robert E. Landry sold 183 shares of the business’s stock in a transaction that occurred on Monday, March 27th. The stock was sold at an average price of $821.70, for a total value of $150,371.10. Following the sale, the chief financial officer now directly owns 32,929 shares in the company, valued at $27,057,759.30. The disclosure for this sale can be found here. Over the last three months, insiders sold 29,986 shares of company stock valued at $23,933,592. Insiders own 8.99% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Barclays boosted their price target on shares of Regeneron Pharmaceuticals from $815.00 to $915.00 and gave the company an “overweight” rating in a research report on Friday, March 24th. Cowen raised shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $775.00 to $875.00 in a research report on Monday, January 30th. BMO Capital Markets lifted their price target on shares of Regeneron Pharmaceuticals from $1,025.00 to $1,040.00 in a research report on Friday, March 24th. Jefferies Financial Group lifted their target price on shares of Regeneron Pharmaceuticals from $925.00 to $940.00 in a report on Thursday, March 30th. Finally, JPMorgan Chase & Co. upped their price target on Regeneron Pharmaceuticals from $900.00 to $950.00 and gave the stock an “overweight” rating in a research note on Friday, March 31st. One investment analyst has rated the stock with a sell rating, four have given a hold rating and nineteen have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $840.87.

Regeneron Pharmaceuticals Trading Up 1.2 %

Regeneron Pharmaceuticals stock opened at $830.35 on Friday. The company has a debt-to-equity ratio of 0.12, a current ratio of 5.06 and a quick ratio of 4.29. The firm’s 50 day moving average price is $778.46 and its 200-day moving average price is $748.56. Regeneron Pharmaceuticals, Inc. has a 1 year low of $538.01 and a 1 year high of $837.55. The stock has a market cap of $90.78 billion, a P/E ratio of 21.71, a PEG ratio of 2.41 and a beta of 0.23.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Rating) last announced its quarterly earnings results on Friday, February 3rd. The biopharmaceutical company reported $12.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.18 by $4.38. Regeneron Pharmaceuticals had a net margin of 35.64% and a return on equity of 22.87%. The company had revenue of $3.41 billion for the quarter, compared to the consensus estimate of $3.11 billion. During the same period in the previous year, the firm posted $23.72 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was down 31.1% compared to the same quarter last year. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 34.05 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Profile

(Get Rating)

Regeneron Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies.